• 153% increase in echocardiograms processed in US from July to September 2025
• Total echocardiograms analysed by EchoSolv AS platform globally exceeds 90,000
• Mayo Clinic Validation study for EchoSolv HF to complete this month, ahead of FDA submission

Echo IQ has reported strong operational momentum with multiple commercial and regulatory milestones achieved. The company has seen a 153% increase in echocardiograms processed through its EchoSolv AS platform with fully integrated US customers from July to September 2025. The total echocardiograms analysed by the EchoSolv AS platform globally has now exceeded 90,000, based on ongoing trials and business development initiatives. The Mayo Clinic Validation study for EchoSolv HF is scheduled to complete this month, prior to the FDA submission for EchoSolv HF shortly thereafter, marking the final regulatory requirement before FDA Clearance. Echo IQ has also completed the onboarding and integration with ScImage, a nationally recognised cloud and integrated workflow management platform with over 1,200 users in the US, and has completed beta testing with SARC MedIQ ahead of broader outreach to 300 healthcare facilities in their network. The company has further strengthened its US presence through the appointment of two new strategic advisors, Dr. Phillipe Genereux and Dr. Asif Ali, both internationally recognised cardiologists. Echo IQ is also in advanced negotiations with a specialist distributor within the European Union to progress sales and regulatory clearance of EchoSolv technology across the region.

The company expects the increase in platform use to flow through to revenue during Q4 CY25, ahead of broader scale-up in CY2026 following an increased level of integrations across US hospital groups and clinics.

Echo IQ is well positioned to accelerate the global adoption of its technology and deliver significant value to shareholders through increased uptake and utilisation of EchoSolv AS in US hospitals, the completion of the Mayo Clinic Validation study and FDA submission for EchoSolv HF, the appointment of new strategic advisors, and the expansion into the European Union market.